Phase 3 Trial from Vertex Studying Ivacaftor in R117H Mutated Cystic Fibrosis Shows Promise in Patients 18+

Completion of Phase 3 Clinical testing by Vertex for their investigational drug, Ivacaftor, in cystic fibrosis (CF) patients who have the R117H mutation, has revealed mixed results. Although Ivacaftor is approved to treat patients with cystic fibrosis and Continue reading Phase 3 Trial from Vertex Studying Ivacaftor in R117H Mutated Cystic Fibrosis Shows Promise in Patients 18+

Sanguine Biosciences is seeking blood donors to help cystic fibrosis researchers.

Individuals with cystic fibrosis can earn $50 from home by donating only a small amount of blood to researchers seeking new treatments, diagnostics and cures. Continue reading Sanguine Biosciences is seeking blood donors to help cystic fibrosis researchers.

Galapagos receives EU2.9 million IWT grant for cystic fibrosis research

MECHELEN, Belgium, Jan. 13, 2014 (GLOBE NEWSWIRE) — Galapagos NV (Euronext: GLPG) announced today that it has been awarded a EUR2.9 million grant from the Flemish agency for Innovation by Science and Technology (IWT) for cystic fibrosis (CF) research. The goal of this 3-year project is to identify and progress multiple promising CF therapies towards pre-clinical candidates . Continue reading Galapagos receives EU2.9 million IWT grant for cystic fibrosis research

Bacterial food web may be key to cystic fibrosis

http://www.news.cornell.edu/stories/2014/01/bacterial-food-web-may-be-key-cystic-fibrosis

Cystic fibrosis patients suffer from chronic bacterial infections and thick mucous in their lungs, due largely to a combination of microbial infections and resulting inflammation. A common pathogen, Continue reading Bacterial food web may be key to cystic fibrosis

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Advanced Inhalation Therapies (AIT Ltd.), an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of Continue reading AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Vertex Pharmaceuticals Incorporated : Patent Issued for Modulators of Cystic Fibrosis Transmembrane Conductance Regulator

http://www.4-traders.com/VERTEX-PHARMACEUTICALS-IN-11321/news/Vertex-Pharmaceuticals-Incorporated–Patent-Issued-for-Modulators-of-Cystic-Fibrosis-Transmembrane-17743040/

By a News Reporter-Staff News Editor at Diabetes Week — A patent by the inventors Yang, Xiaoqing (San Diego, CA); Hadida Ruah, Sara Sabina (La Jolla, CA); Grootenhuis, Peter Diederik Jan (San Diego, CA); Continue reading Vertex Pharmaceuticals Incorporated : Patent Issued for Modulators of Cystic Fibrosis Transmembrane Conductance Regulator

Potential new drug target for cystic fibrosis

 Large-scale screen also identified genes not previously linked to the disease
http://www.thealmagest.com/potential-new-drug-target-cystic-fibrosis/3775

Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Regensburg University, both in Germany, and the University of Lisboa, in Portugal, have discovered a Continue reading Potential new drug target for cystic fibrosis

MRSA trial now recruiting patients

A new phase II trial is currently recruiting cystic fibrosis (CF) patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection to determine the effectiveness, safety, and pharmacokinetics of a new investigational inhalable powder formulation of vancomycin called Continue reading MRSA trial now recruiting patients

Cost of cystic fibrosis drug, others threatens system, doctors say

At a cost of more than $300,000 a year, the new cystic fibrosis drug, Kalydeco, is one of the most expensive pills in American medicine. In early October, three doctors who treat cystic fibrosis patients said that kind of extremely high pricing for new drugs that treat rare conditions threatens the U.S. health care system and can’t be sustained.

Continue reading Cost of cystic fibrosis drug, others threatens system, doctors say

KaloBios Says Cystic Fibrosis-Related Treatment Gains Orphan-Drug Status

KaloBios Pharmaceuticals Inc. (KBIO) said the U.S. Food and Drug Administration granted orphan-drug designation for its treatment for cystic fibrosis patients with Pseudomonas aeruginosa. Continue reading KaloBios Says Cystic Fibrosis-Related Treatment Gains Orphan-Drug Status